A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma

• Published in: Frontiers in immunology Vol. 14; p. 1014378
• Main Authors: Lei, Qiang, Yuan, Bo, Liu, Kun, Peng, Li, Xia, Zhiwei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 11.04.2023
• Subjects: Adult; amino acid; Amino Acids; Glioblastoma; glioma; Glioma - genetics; Humans; Immunology; lncRNA; Prognosis; prognostic; RNA, Long Noncoding - genetics; target; prognostic; glioma; lncRNA; amino acid; target
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1014378

Glioma is one of the deadliest malignant brain tumors in adults, which is highly invasive and has a poor prognosis, and long non-coding RNAs (lncRNAs) have key roles in the progression of glioma. Amino acid metabolism reprogramming is an emerging hallmark in cancer. However, the diverse amino acid metabolism programs and prognostic value remain unclear during glioma progression. Thus, we aim to find potential amino-related prognostic glioma hub genes, elaborate and verify their functions, and explore further their impact on glioma. Glioblastoma (GBM) and low-grade glioma (LGG) patients' data were downloaded from TCGA and CCGA datasets. LncRNAs associated with amino acid metabolism were discriminated against correlation analysis. LASSO analysis and Cox regression analysis were conducted to identify lncRNAs related to prognosis. GSVA and GSEA were performed to predict the potential biological functions of lncRNA. Somatic mutation data and CNV data were further built to demonstrate genomic alterations and the correlation between risk scores. Human glioma cell lines U251 and U87-MG were used for further validation experiments. There were eight amino-related lncRNAs in total with a high prognostic value that were identified Cox regression and LASSO regression analyses. The high risk-score group presented a significantly poorer prognosis compared with the low risk-score group, with more clinicopathological features and characteristic genomic aberrations. Our results provided new insights into biological functions in the above signature lncRNAs, which participate in the amino acid metabolism of glioma. LINC01561 is one of the eight identified lncRNAs, which was adopted for further verification. In experiments, siRNA-mediated LINC01561 silencing suppresses glioma cells' viability, migration, and proliferation. Novel amino-related lncRNAs associated with the survival of glioma patients were identified, and a lncRNA signature can predict glioma prognosis and therapy response, which possibly has vital roles in glioma. Meanwhile, it emphasized the importance of amino acid metabolism in glioma, particularly in providing deeper research at the molecular level.